Controlling extracellular matrix degradation: is the promised land in sight? Or why I take a matrix metalloproteinase inhibitor every morning.
Greenwald
R A
RA
Department of Medicine, Albert Einstein College of Medicine, State University of New York at Stony Brook, USA. rgreen@lij.edu
D001168:Arthritis / Q000188:drug therapy / Q000209:etiology; D017364:Collagenases / Q000009:adverse effects; D015507:Drugs, Investigational; D005109:Extracellular Matrix / Q000201:enzymology*; D018093:Gelatinases / Q000009:adverse effects / Q000037:antagonists & inhibitors; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000009:adverse effects / Q000737:chemistry; D009626:Terminology as Topic
D015507:Drugs, Investigational; D061965:Matrix Metalloproteinase Inhibitors; D017364:Collagenases; D018093:Gelatinases; D020782:Matrix Metalloproteinases